Showing 8791-8800 of 20403 results for "".
Understanding Quality of Life in COPD Through Photovoice
https://reachmd.com/programs/clinicians-roundtable/copd-quality-of-life-photovoice/54215/New Evidence on Biologics in Severe Asthma with Normal Lung Function
https://reachmd.com/programs/clinicians-roundtable/biologics-severe-asthma-normal-lung-function/54179/Optimizing Vitamin D Supplementation in MS Care
https://reachmd.com/programs/neurofrontiers/vitamin-d-supplementation-ms/54244/A Busy Time in the Field
https://reachmd.com/issues/januaryfebruary-2026/a-busy-time-in-the-field/54452/Managing Unexpected Aesthetic Changes Associated with the Use of GLP-1 Receptor Agonists
https://reachmd.com/ma-issues-index/jan-feb-2026-issue/managing-unexpected-aesthetic-changes-associated-with-the-use-of-glp-1-receptor-agonists/54441/Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
https://reachmd.com/programs/heart-matters/diagnosis-attr-cm-underserved-populations/49051/The Case for Doing the Hard Thing
https://reachmd.com/topics/practice-development/the-case-for-doing-the-hard-thing/49010/Managing PNH Patients: Addressing the Unmet Needs
https://reachmd.com/programs/project-oncology/managing-pnh-patients-addressing-the-unmet-needs/48881/What are the current knowledge gaps when it comes to managing patients with PNH? Here's what you need to know.APOL1 Screening and Early Detection: Patient and Clinician Perspectives
https://reachmd.com/programs/kdigo-conversations-nephrology/apol1-screening-and-early-detection-patient-and-clinician-perspectives/35712/APOL1 Screening and Early Detection: Patient and Clinician PerspectivesCohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
https://reachmd.com/clinical-practice/oncology-hematology/cohort-9-of-the-phase-2-ev-202-trial-first-line-enfortumab-vedotin-plus-pembrolizumab-in-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma/39779/In cohort 9 of EV-202, first-line enfortumab vedotin plus pembrolizumab showed promising and durable responses in patients with recurrent or metastatic HNSCC.